Marc de Garidel, Abivax CEO
October 20, 2023 11:07 AM EDTUpdated 12:03 PM
Financing

French biotech Abi­vax makes Nas­daq de­but, aim­ing to raise $236M to get PhI­II da­ta in IBD

Andrew Dunn

Senior Biopharma Correspondent

Abi­vax start­ed trad­ing Fri­day on the Nas­daq, as the decade-old Paris-based start­up aims to raise about $236 mil­lion to get Phase III re­sults for its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times